News From Industry Sources
NeurogesX announces presentation of positive phase 3 clinical data at the Second International Congress On Neuropathic Pain meeting (NeuPSIG)
June 8, 2007
Phase 3 trial demonstrates NGX-4010 is effective both alone and in combination with other neuropathic pain medications for the treatment of postherpetic neuralgia.
Story
Vertebration's Xycor Spinal Implant receives FDA 510(k) clearance
The XYcor™ Spinal Implant is designed to restore and maintain biomechanical integrity throughout the thoracolumbar spine following vertebrectomy or corpectomy for patients with spinal tumors or fractures. Story
Meditrac presents its innovative concept for treatment of chronic neck and back pain at the World Physical Therapy Congress in Vancouver
May 29, 2007
Meditrac presented its new "Traction on the Move" concept
at the World Physical Therapy 2007 Story
Forest Laboratories, Inc. and Cypress Bioscience, Inc. announce positive results of phase III study for milnacipran as a treatment for fibromyalgia syndrome
May 22, 2007
The primary pre-defined endpoints of this trial were composite responder assessments to evaluate either the treatment of the pain associated with fibromyalgia syndrome or the overall treatment of fibromyalgia syndrome. Story
New breakthrough treatment for spinal cancer patients shrinks tumors, eliminates pain
May 17, 2007
The Mount Sinai Medical Center is the only hospital in New York City using the Novalis Shaped Beam Surgery System on spinal cancer. Novalis is the most advanced Stereotactic Radiosur-gery(SRS) technology available to treat cancer tumors in the spine. Story
Ulcerative colitis (UC) sufferers find UC quite disruptive to many aspects of daily life
May 17, 2007
Nearly three out of four ulcerative colitis (UC) sufferers (73 percent) responding to a new nationwide survey say not feeling well has become a normal part of life. Furthermore, they describe UC as disruptive when it comes to their relationship with a spouse (64 percent), their sexual relations (75 percent) and their emotional state (82 percent). Story
BDSI announces positive key secondary efficacy endpoint results for BEMA(TM) Fentanyl
May 14, 2007
BEMA Fentanyl Phase III data demonstrates statistical significance compared to placebo in relieving pain within 15 minutes in patients with breakthrough cancer pain. Story
Data Suggest Cymbalta® Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
May 3, 2007
Data from a pooled analysis of three studies suggest that in patients with pain caused by diabetic nerve damage, or diabetic peripheral neuropathy, who are treated with Cymbalta (duloxetine HCl), improvements in both average daily pain and night pain severity were associated with less pain-related sleep interference than in those patients taking sugar pill. Story
|
